• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Travere Therapeutics, Inc.

< Previous 1 2 3 Next >
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 12, 2025
From Travere Therapeutics, Inc.
Via Business Wire
Tickers TVTX
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference
June 11, 2025
From Travere Therapeutics, Inc.
Via Business Wire
Tickers TVTX
Travere Therapeutics Launches "Play It Forward" Campaign to Celebrate the FSGS Community on Inaugural Awareness Day
June 10, 2025
From Travere Therapeutics, Inc.
Via Business Wire
Tickers TVTX
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress
June 03, 2025
From Travere Therapeutics, Inc.
Via Business Wire
Tickers TVTX
Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS
May 15, 2025
From Travere Therapeutics, Inc.
Via Business Wire
Tickers TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 12, 2025
From Travere Therapeutics, Inc.
Via Business Wire
Tickers TVTX
Travere Therapeutics to Participate at Upcoming Investor Conferences
May 07, 2025
From Travere Therapeutics, Inc.
Via Business Wire
Tickers TVTX
Travere Therapeutics Reports First Quarter 2025 Financial Results
May 01, 2025
From Travere Therapeutics, Inc.
Via Business Wire
Tickers TVTX
Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy
April 29, 2025
From Travere Therapeutics, Inc.
Via Business Wire
Tickers TVTX
Travere Therapeutics to Report First Quarter 2025 Financial Results
April 24, 2025
From Travere Therapeutics, Inc.
Via Business Wire
Tickers TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 11, 2025
From Travere Therapeutics, Inc.
Via Business Wire
Tickers TVTX
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025
March 31, 2025
From Travere Therapeutics, Inc.
Via Business Wire
Tickers TVTX
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS
March 17, 2025
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 12, 2025
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics to Participate at Upcoming Investor Conferences
February 24, 2025
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
February 20, 2025
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
February 13, 2025
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 12, 2025
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS
February 11, 2025
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics Provides Corporate Update and 2025 Outlook
January 13, 2025
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 06, 2025
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics to Present at Upcoming Investor Conferences
November 25, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 13, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
November 12, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics Announces Pricing of Public Offering of Common Stock
November 07, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics Announces Proposed Public Offering of Common Stock
November 07, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics to Present at Upcoming Investor Conferences
November 04, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics Reports Third Quarter 2024 Financial Results
October 31, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024
October 26, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics to Report Third Quarter 2024 Financial Results
October 21, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
< Previous 1 2 3 Next >
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap